Navigation Links
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
Date:7/30/2009

LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human antibody drug discovery company with world class expertise in targeting multi-spanning membrane proteins, announce the signature of an exclusive agreement for the development and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.

Under the terms of the agreement, Debiopharm and MSM haveformed a partnership to select antibodies against the GPCR. Upon completion of the discovery phase, MSM will grant Debiopharm a worldwide exclusive licence for the development and commercialisation of the antibody. MSM will retain marketing rights for Russia, Ukraine and several other countries in Eastern Europe and Asia. MSM will receive milestone payments from Debiopharm during the development of the product, as well as a share of royalties on net sales.

"We usually licence-in compounds with existing animal proof of concept, but we were seduced by MSM's technology and their expertise in the generation of antibodies aimed at GPCRs," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "This is a win-win situation, our companies complement one another. MSMs discovery expertise, together with our experience in drug development should lead to innovative oncology therapeutics."

"This is a transformational deal for MSM because it represents our first jointly owned program with a global partner. We are pleased to be working with Debiopharm because they are an excellent company that complements MSM's skill set. We are also happy to be among Debiopharm's partners in the antibody space," added Davis Farmer, MSM's Cha
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
2. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
3. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
4. Japanese Cancer Association and Debiopharm Honour Japanese Research
5. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
6. Debiopharm and EPFL Establish an Oncology Chair
7. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
8. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
9. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
10. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
11. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...NTACRUZ,Calif.,Nov.24/PRNewswire/--Twomoreprestigi...,sleadingonlinejobboardandcareerssiteforlifescienc...rsityarenowmembersofthejobboard,joining28othermajo...d, www.biocareercenter.com ,isonlyforpost-graduate...ncecareersitesontheInternet,BioCareerCenteristheon...
(Date:11/24/2009)...YKJAVIK,Iceland,November24/PRNewswire-FirstCall/--...hatithasreceivednoticefrom,theNasdaqStockMarkettha...sofNovember30,2009andaForm25-NSEwillbefiledwiththe...CODE,scommonstock,fromlistingonNasdaq,unlessthecom...Panel.Thecompanyhasfiledsuchanappeal,which,willsta...
(Date:11/24/2009)... Health care employment grew by 2...nly one to show consistent growth during the U.S. ...s remain in trouble, and health systems are coming...l, instead of just administrators. , ...re employment continued growing in October despite...
(Date:11/24/2009)...ANGHAI,Nov.24/PRNewswire-Asia/--NODPharmaceuticals...hasallowedthepatentapplicationfor,itsnano-particle...sahighlyefficientapproachtoincorporatepeptidesor,p...eliveryofdrugs,otherwiseadministeredasinjections.N...tomanymacromoleculardrugssuchasinsulin,interferon,...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
...ls,Inc. (Nasdaq: CADX ), a biopharmaceutical comp...ializing proprietary product candidates principall... that the company,s,President and CEO Theodore Sch...ew on Tuesday, October 28, 2008 at 9:30am Pacific ...stor Conference at the Hyatt Aventine,La Jolla Hot...
...nounced that it,has provided a GOLD facility for t...) by MTS Health Investors, LLC (MTS). GOLD financi...cilities. Terms of the,transaction were not disclo...e largest and most reputable,DNA testing laborator...dentification testing for the private sector. The ...
...esults (all percentage comparisons are to comparab... Consistent Research Sales Gain: Q3 2008 sales ...3.1% to organic growth of 4.3%. Q3 organic sal...ased sales units was in-line with the 6.9% gain fo...ncy adjusted sales for SAFC decreased by 2.0% ...
Other Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIOCOM Investor Conference 2Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 11Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 12Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 13Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 14Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 15Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 16Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 17Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 18Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 19Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 20
(Date:11/25/2009)..., police officers and ambulance workers faced a te...omplex. They battled to save people from the colla... fires and evacuated as many people as they could ...ple. And making their jobs even harder was the pro...d their relatives jammed mobile networks with call...
(Date:11/25/2009)...y be just as vital to your health as what you eat,...gical Studies. Their experiments in mice revealed ...enes in the liverthe body,s metabolic clearinghous...e body,s circadian clock as conventional wisdom ha...y of a large number of genes completely independen...
(Date:11/24/2009)... flabby arteries from collapsing have been true li...no longer needed -- once the arteries are strength... had no choice but to leave them in place. , Pro...tment of Biomedical Engineering has developed a ne... where they,re needed, then dissolves. , "Our ne...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 1Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 2Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 3Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 1Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 2Is your environment damaging your health 3F New center aims to find out 47466 1Is your environment damaging your health 3F New center aims to find out 47466 2Is your environment damaging your health 3F New center aims to find out 47466 3
...The cell-signaling molecule Akt is a primary trigg...rface to begin growing vertically beneath the skin... have found. Understanding this key molecular dif...e surface of the skin and melanomas that grow vert...r the development of drugs to treat individuals wi...
...A popular game fish mistaken by scientists for a d...ong the reefs of the Abrolhos region of the South ...l Zootaxa announced the discovery of Lutjanus alex...Lutjanidae family, by researchers Rodrigo Moura of...an of Environmental Defense. The study published i...
...A UCL (University College London) study has found ... not think too hard and instead trust your instinc...urnal Current Biology, shows that, in some cases, ...decisions taken using higher-level cognitive proce...dd one out on a screen covered in over 650 identic...
Other Biology News:Molecular differences between early and advanced melanomas could provide new drug targets 2New species of snapper discovered in Brazil 2Trusting your instincts leads you to the right answer 2Trusting your instincts leads you to the right answer 3
Mouse Anti-Human Cystatin A Monoclonal Antibody, Unconjugated, Clone 224705 from R&D Systems
Acc I from Takara Mirus Bio
Microlite 2+ Plate from Thermo Scientific
... low temperature freezers offer a superior sample ...samples with high capacities. Innovative insulatio... excellent warming protection and ensure low energ...fy tracking of sample location and maximize sample...
Biology Products: